The same group also demonstrated that the NLRP3/caspase-1/IL-1β signaling axis acts as a key character in the progression of steatosis, the inflammatory response and cellular injury in ALD, and that inhibiting the IL-1 signaling pathway alleviated these symptoms (Petrasek et al., 2012). The gene discussed is NLRP3; the disease is steatosis.